Business Description
Patrys Limited is an Australian biotech company focused on developing antibody-based treatments for cancer and inflammatory diseases. Its two lead programs, PAT-DX1 and PAT-DX3, are small antibody fragments designed to target brain tumors and conditions linked to a process called NETosis, where the immune system triggers harmful inflammation. The treatments are also being explored alongside existing therapies such as radiation and chemotherapy. Founded in 2006, the company operates out of Nedlands, Australia.
